AR117916A1 - Compuesto heterocíclico y su uso - Google Patents
Compuesto heterocíclico y su usoInfo
- Publication number
- AR117916A1 AR117916A1 ARP200100236A ARP200100236A AR117916A1 AR 117916 A1 AR117916 A1 AR 117916A1 AR P200100236 A ARP200100236 A AR P200100236A AR P200100236 A ARP200100236 A AR P200100236A AR 117916 A1 AR117916 A1 AR 117916A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- optionally substituted
- substituents selected
- alkoxy
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- 102000002512 Orexin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 108060005714 orexin Proteins 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- -1 carbon atom halogen Chemical class 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente proporciona un compuesto heterocíclico que tiene actividad de un agonista del receptor de orexina tipo 2. Un compuesto representado por la fórmula [1] en donde cada símbolo es como se describe en la memoria descriptiva, o una de sus sales tiene una actividad del agonista del receptor de orexina tipo 2, y es útil como un agente para la profilaxis o tratamiento de la narcolepsia. Reivindicación 1: Un compuesto representado por la fórmula [1] caracterizado porque R¹ es (1) un grupo alquilo C₁₋₆, (2) un grupo mono o dialquilamino C₁₋₆, o (3) un grupo cicloalquilo C₃₋₆; R² es (1) un átomo de hidrógeno, (2) un átomo de flúor, o (3) un grupo alquilo C₁₋₆; R³ es (1) un grupo alquilo C₁₋₆ carbonilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de (a) un átomo de halógeno, (b) un grupo hidroxi, y (c) un grupo ciano, (2) un grupo alcoxi C₁₋₆ carbonilo, (3) un grupo cicloalquil C₃₋₁₀ carbonilo (el resto cicloalquilo C₃₋₁₀ del grupo cicloalquil C₃₋₁₀ carbonilo está opcionalmente unido con puente) opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de (a) un átomo de halógeno, (b) un grupo hidroxi, (c) un grupo ciano, y (d) un grupo alquilo C₁₋₆, (4) un grupo heterociclilcarbonilo no aromático de 3 a 14 miembros opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de (a) un átomo de halógeno, (b) un grupo hidroxi, y (c) un grupo alquilo C₁₋₆, (5) un grupo mono o dialquil C₁₋₆ carbamoílo, (6) un grupo N-alquil C₁₋₆-N-alcoxi C₁₋₆-carbamoílo, o (7) un grupo N-alquil C₁₋₆-N,N-di-alquil C₁₋₆hidrazina-carbonilo; y el Anillo A es (1) un anillo benceno también sustituido con un sustituyente seleccionado de (a) un grupo arilo C₆₋₁₄ opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de (i) un átomo de halógeno, (ii) un grupo alquilo C₁₋₆ opcionalmente halogenado, y (iii) un grupo alcoxi C₁₋₆ opcionalmente halogenado, y (b) un grupo heterocíclico aromático de 5 a 14 miembros opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de (i) un grupo alquilo C₁₋₆ opcionalmente sustituido con 1 a 3 sustituyentes seleccionados de un átomo de halógeno y un grupo hidroxi, (ii) un grupo alcoxi C₁₋₆, (iii) un átomo de halógeno, y (iv) un grupo alcoxi C₁₋₆ carbonilo, y opcionalmente también sustituidos con 1 a 3 átomos de halógeno, o (2) un heterociclo aromático de 5 ó 6 miembros también sustituido con un grupo arilo C₆₋₁₄ opcionalmente sustituido con 1 a 3 átomos de halógeno, o una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019015488 | 2019-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117916A1 true AR117916A1 (es) | 2021-09-01 |
Family
ID=69770989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100236A AR117916A1 (es) | 2019-01-31 | 2020-01-30 | Compuesto heterocíclico y su uso |
Country Status (32)
| Country | Link |
|---|---|
| US (7) | US20230040770A1 (es) |
| EP (2) | EP3917616B1 (es) |
| JP (2) | JP7253640B2 (es) |
| KR (1) | KR102882779B1 (es) |
| CN (6) | CN118420600A (es) |
| AR (1) | AR117916A1 (es) |
| AU (1) | AU2020215380B2 (es) |
| BR (1) | BR112021014180A2 (es) |
| CA (1) | CA3124536A1 (es) |
| CL (1) | CL2021001973A1 (es) |
| CO (1) | CO2021011188A2 (es) |
| DK (1) | DK3917616T3 (es) |
| EA (1) | EA202192138A1 (es) |
| EC (1) | ECSP21056325A (es) |
| ES (1) | ES3037650T3 (es) |
| FI (1) | FI3917616T3 (es) |
| HR (1) | HRP20250785T1 (es) |
| HU (1) | HUE071890T2 (es) |
| IL (1) | IL284073B2 (es) |
| LT (1) | LT3917616T (es) |
| MX (1) | MX2021008241A (es) |
| MY (1) | MY209784A (es) |
| PE (1) | PE20211700A1 (es) |
| PH (1) | PH12021551846A1 (es) |
| PL (1) | PL3917616T3 (es) |
| PT (1) | PT3917616T (es) |
| RS (1) | RS67170B1 (es) |
| SG (1) | SG11202106791XA (es) |
| SI (1) | SI3917616T1 (es) |
| TW (1) | TWI832962B (es) |
| WO (1) | WO2020158958A1 (es) |
| ZA (1) | ZA202106304B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125597C2 (uk) * | 2017-08-03 | 2022-04-27 | Такеда Фармасьютікал Компані Лімітед | Гетероциклічна сполука та її застосування |
| CN118420600A (zh) | 2019-01-31 | 2024-08-02 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| EP4065585B1 (en) | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7665527B2 (ja) | 2019-11-27 | 2025-04-21 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20231384A1 (es) | 2020-08-18 | 2023-09-12 | Merck Sharp And Dohme Llc | Agonistas de bicicloheptano pirrolidina de los receptores de orexina |
| TW202227433A (zh) * | 2020-09-03 | 2022-07-16 | 英商歐瑞夏治療公司 | 中環或大環之經苄基取代的雜環衍生物及相關用途 |
| CN116583502A (zh) * | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| JP2022064180A (ja) * | 2020-10-13 | 2022-04-25 | 武田薬品工業株式会社 | 複素環化合物 |
| KR20230104193A (ko) * | 2020-11-02 | 2023-07-07 | 머크 샤프 앤드 돔 엘엘씨 | 마크로시클릭 우레아 오렉신 수용체 효능제 |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022207935A1 (en) * | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| US20240165092A1 (en) | 2021-04-02 | 2024-05-23 | Takeda Pharmaceutical Limited Company | Use of an orexin 2 receptor agonist for post operation recovery |
| KR20240157067A (ko) | 2022-03-01 | 2024-10-31 | 센테사 파마슈티칼스 (유케이) 리미티드 | 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 |
| WO2023199091A1 (en) | 2022-04-12 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| IL319940A (en) | 2022-10-07 | 2025-05-01 | Kissei Pharmaceutical | Cyclopentane compound |
| JP7592226B1 (ja) | 2022-10-31 | 2024-11-29 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2024095158A1 (en) | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| AU2023403030A1 (en) | 2022-11-30 | 2025-06-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| AU2023395547A1 (en) | 2022-12-16 | 2025-06-26 | Daiichi Sankyo Company, Limited | 2-azabicyclo[3.1.1]heptane compound |
| IL322817A (en) | 2023-03-16 | 2025-10-01 | Takeda Pharmaceuticals Co | Macrocyclic heterocyclic compounds and their uses |
| TW202502342A (zh) * | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| GB202404750D0 (en) | 2024-04-03 | 2024-05-15 | Bial Portela & Ca Sa | Orexin receptor agonists |
| WO2025211415A1 (ja) * | 2024-04-04 | 2025-10-09 | キッセイ薬品工業株式会社 | 置換スルホンアミド化合物 |
| WO2025211416A1 (ja) * | 2024-04-04 | 2025-10-09 | キッセイ薬品工業株式会社 | 置換スルホンアミド大環状化合物 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2025229495A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2025229494A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US20250375417A1 (en) | 2024-05-01 | 2025-12-11 | Takeda Pharmaceutical Company Limited | Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1) |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1028305A (en) | 1911-03-04 | 1912-06-04 | Nicholas King Turnbull | Machine for remaking wire-drawing dies. |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| DE60045005D1 (de) | 1999-06-28 | 2010-11-04 | Oklahoma Med Res Found | Inhibitoren des memapsin 2 und ihre verwendung |
| AU6615300A (en) | 1999-07-30 | 2001-02-19 | Board Of Trustees Of The Leland Stanford Junior University | Hypocretin and hypocretin receptors in regulation of sleep and related disorders |
| US7112566B1 (en) | 1999-09-17 | 2006-09-26 | The Regents Of The University Of California | Systemic administration of Hypocretin-1 |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| AU2001251306A1 (en) | 2000-04-04 | 2001-10-15 | Siegel, Jerome M. | Treatment of sleep disorders with hypocretin-1 |
| CA2498264A1 (en) | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
| US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| DE60320302T2 (de) | 2002-12-13 | 2009-05-20 | Janssen Pharmaceutica N.V. | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors |
| HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| JP5232987B2 (ja) | 2006-04-14 | 2013-07-10 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物 |
| AU2012200270A1 (en) * | 2007-05-23 | 2012-02-09 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
| US20110053859A1 (en) | 2007-10-10 | 2011-03-03 | The U. S. Government Respresented by the Department of Veterans Affairs | Methods to reduce the effects of sleep deprivation |
| WO2009111064A2 (en) | 2008-03-05 | 2009-09-11 | Paratek Pharmaceuticals, Inc. | Minocycline compounds and methods of use thereof |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| JP5976011B2 (ja) * | 2011-04-05 | 2016-08-23 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
| TW201341380A (zh) * | 2012-04-05 | 2013-10-16 | Takeda Pharmaceutical | 磺醯胺衍生物及其用途 |
| AR092955A1 (es) | 2012-10-10 | 2015-05-06 | Actelion Pharmaceuticals Ltd | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona |
| WO2014170343A1 (en) | 2013-04-15 | 2014-10-23 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| US9815787B2 (en) | 2013-12-12 | 2017-11-14 | University Of Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
| UY36272A (es) | 2014-08-13 | 2016-02-29 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores de los receptores de orexinas |
| EP3029024A1 (en) | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| KR20240051297A (ko) | 2015-03-24 | 2024-04-19 | 파라테크 파마슈티컬스, 인크. | 생물방어를 위한 미노시클린 화합물 |
| EP3309146A4 (en) | 2015-06-12 | 2019-02-27 | University of Tsukuba | SULPHONAMID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITIVE SALT THEREOF |
| US10980755B2 (en) | 2015-09-10 | 2021-04-20 | The Regents Of The University Of California | LRH-1 modulators |
| PT3984994T (pt) * | 2016-02-04 | 2024-10-10 | Takeda Pharmaceuticals Co | Composto de piperidina substituída como agonista de orexina tipo 2 para o tratamento da narcolepsia |
| JP6957598B2 (ja) * | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| UA125597C2 (uk) * | 2017-08-03 | 2022-04-27 | Такеда Фармасьютікал Компані Лімітед | Гетероциклічна сполука та її застосування |
| EP3663281B1 (en) | 2017-08-03 | 2022-12-28 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JPWO2019112007A1 (ja) | 2017-12-07 | 2020-12-24 | 国立大学法人 筑波大学 | 鎮痛薬による眠気の予防または治療薬 |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US12071434B2 (en) | 2018-12-12 | 2024-08-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TWI834784B (zh) | 2018-12-20 | 2024-03-11 | 美商Ｋｓｑ治療公司 | 經取代之吡唑并嘧啶及經取代之嘌呤以及其作為泛素特異性加工蛋白酶１ （ ｕ ｓ ｐ １ ） 抑制劑的用途 |
| EP3917913A2 (en) | 2019-01-31 | 2021-12-08 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| CN118420600A (zh) | 2019-01-31 | 2024-08-02 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2020
- 2020-01-30 CN CN202410143991.2A patent/CN118420600A/zh active Pending
- 2020-01-30 US US17/427,490 patent/US20230040770A1/en not_active Abandoned
- 2020-01-30 KR KR1020217024931A patent/KR102882779B1/ko active Active
- 2020-01-30 PL PL20709748.6T patent/PL3917616T3/pl unknown
- 2020-01-30 US US16/777,273 patent/US11028048B2/en active Active
- 2020-01-30 PE PE2021001139A patent/PE20211700A1/es unknown
- 2020-01-30 CN CN202410132356.4A patent/CN118290408A/zh active Pending
- 2020-01-30 TW TW109102825A patent/TWI832962B/zh active
- 2020-01-30 CN CN202080011417.1A patent/CN113395993B/zh active Active
- 2020-01-30 RS RS20250877A patent/RS67170B1/sr unknown
- 2020-01-30 WO PCT/JP2020/004444 patent/WO2020158958A1/en not_active Ceased
- 2020-01-30 CN CN202410149044.4A patent/CN118271298A/zh active Pending
- 2020-01-30 DK DK20709748.6T patent/DK3917616T3/da active
- 2020-01-30 AR ARP200100236A patent/AR117916A1/es unknown
- 2020-01-30 IL IL284073A patent/IL284073B2/en unknown
- 2020-01-30 CN CN202410125823.0A patent/CN118344346A/zh active Pending
- 2020-01-30 HR HRP20250785TT patent/HRP20250785T1/hr unknown
- 2020-01-30 SI SI202030637T patent/SI3917616T1/sl unknown
- 2020-01-30 PH PH1/2021/551846A patent/PH12021551846A1/en unknown
- 2020-01-30 CA CA3124536A patent/CA3124536A1/en active Pending
- 2020-01-30 JP JP2021568451A patent/JP7253640B2/ja active Active
- 2020-01-30 SG SG11202106791XA patent/SG11202106791XA/en unknown
- 2020-01-30 HU HUE20709748A patent/HUE071890T2/hu unknown
- 2020-01-30 EP EP20709748.6A patent/EP3917616B1/en active Active
- 2020-01-30 EA EA202192138A patent/EA202192138A1/ru unknown
- 2020-01-30 AU AU2020215380A patent/AU2020215380B2/en active Active
- 2020-01-30 FI FIEP20709748.6T patent/FI3917616T3/fi active
- 2020-01-30 ES ES20709748T patent/ES3037650T3/es active Active
- 2020-01-30 EP EP25176476.7A patent/EP4578853A3/en active Pending
- 2020-01-30 CN CN202410118961.6A patent/CN118271297A/zh active Pending
- 2020-01-30 PT PT207097486T patent/PT3917616T/pt unknown
- 2020-01-30 MY MYPI2021004342A patent/MY209784A/en unknown
- 2020-01-30 BR BR112021014180-4A patent/BR112021014180A2/pt unknown
- 2020-01-30 LT LTEPPCT/JP2020/004444T patent/LT3917616T/lt unknown
- 2020-01-30 MX MX2021008241A patent/MX2021008241A/es unknown
-
2021
- 2021-04-23 US US17/239,191 patent/US20210276949A1/en not_active Abandoned
- 2021-07-27 CL CL2021001973A patent/CL2021001973A1/es unknown
- 2021-07-30 EC ECSENADI202156325A patent/ECSP21056325A/es unknown
- 2021-08-25 CO CONC2021/0011188A patent/CO2021011188A2/es unknown
- 2021-08-30 ZA ZA2021/06304A patent/ZA202106304B/en unknown
-
2023
- 2023-03-27 JP JP2023050325A patent/JP7502512B2/ja active Active
- 2023-11-27 US US18/520,037 patent/US20240360080A1/en not_active Abandoned
-
2025
- 2025-03-13 US US19/079,211 patent/US12415782B2/en active Active
- 2025-03-13 US US19/079,172 patent/US12421188B2/en active Active
- 2025-03-13 US US19/079,199 patent/US12404237B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117916A1 (es) | Compuesto heterocíclico y su uso | |
| AR113842A1 (es) | Derivados de tiazol microbiocidas | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| UY30830A1 (es) | Piperidinas sustituidas que presentan actividad inhibitoria de proteinquinasa | |
| BRPI0607062A2 (pt) | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos | |
| AR088610A1 (es) | Compuestos plaguicidas | |
| ES2188016T3 (es) | Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas. | |
| ES2191484T3 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| DOP2012000318A (es) | Compuestos heterociclicos fusionados | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| ECSP088805A (es) | 2-(piridin-2-il)-pirimidinas como fungicidas | |
| ES2553030T3 (es) | Compuestos plaguicidas | |
| MX2021008252A (es) | Compuesto de pirimidina o sal del mismo. | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR095059A1 (es) | Compuestos herbicidas | |
| CR7249A (es) | Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo | |
| CO6300944A2 (es) | Derivado de hidroxi-quinoxalin-carboxamida | |
| CO5660292A2 (es) | Pirimidinas 2-sustituidas | |
| AR113931A1 (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas | |
| AR115020A1 (es) | Compuesto heterocíclico nitrogenado y su uso como antagonista del receptor nmda | |
| AR095895A1 (es) | Compuestos de acil-imino-piridina n-sustituidos y derivados para combatir plagas de animales |